Overview

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Pfizer

Treatments:

Donepezil